Contraceptive Pills Market by Product, Age Group (15-24, 25-34, 35-44), Drug Class, Mode of Prescription, Distribution, Route of Administration

List of Tables

The Contraceptive Pills Market was valued at USD 19.53 billion in 2023, expected to reach USD 20.76 billion in 2024, and is projected to grow at a CAGR of 6.46%, to USD 30.27 billion by 2030.

The contraceptive pills market is defined by its role in preventing pregnancy through hormonal formulations that inhibit ovulation. It encompasses various types, including combined oral contraceptives (estrogen and progestin) and progestin-only pills, catering primarily to women in reproductive age groups. The necessity of contraceptive pills stems from the increasing awareness of family planning, the need for effective pregnancy prevention methods, and the empowerment of women in making reproductive choices. These pills find applications not only in contraception but also in managing menstrual disorders, acne, and endometriosis, extending their end-use scope across diverse demographics. Market growth is heavily influenced by rising educational levels, increasing access to healthcare, and growing governmental support for birth control measures. Recent advancements in lower dosage pills and the introduction of extended-cycle pills present potential opportunities for market expansion. To tap into these opportunities, companies should focus on enhancing affordability, expanding distribution channels, and raising awareness through education campaigns. However, challenges such as the perceived risk of side effects, ethical and religious opposition, and regulatory restrictions could impede market expansion. Additionally, market penetration is limited in some regions due to cultural biases and lack of awareness. Innovations in the field are ripe in the areas of developing non-hormonal pills, personalized medicine approaches, and digital health solutions for better medication adherence and tracking. These innovations, alongside strategic partnerships with healthcare providers, can drive business growth. The market exhibits a dynamic, albeit fragmented nature, indicating potential consolidation through mergers and acquisitions. Overall, staying attuned to evolving needs and perceptions, investing in R&D, and focusing on personalized experiences will be crucial for capturing growth in this competitive yet promising market.

KEY MARKET STATISTICS
Base Year [2023]	USD 19.53 billion
Estimated Year [2024]	USD 20.76 billion
Forecast Year [2030]	USD 30.27 billion
CAGR (%)	6.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Contraceptive Pills Market

The Contraceptive Pills Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing use of contraceptive pills to prevent unintended pregnancies and rising awareness about family planning
- Growing prevalence of sexually transmitted diseases (STDs)
- Supportive government initiatives to encourage use of contraceptive pills
Market Restraints
- Incidences of product recalls & adverse health impacts of contraceptive pills
Market Opportunities
- Ongoing advancements in contraceptive pill formulations and packaging
- Availability of contraceptive pills through online channels
Market Challenges
- Safety and social concerns regarding pill usage and issues with product marketing

Porter's Five Forces: A Strategic Tool for Navigating the Contraceptive Pills Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Contraceptive Pills Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Contraceptive Pills Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Contraceptive Pills Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Contraceptive Pills Market

A detailed market share analysis in the Contraceptive Pills Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Contraceptive Pills Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Contraceptive Pills Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Contraceptive Pills Market

A strategic analysis of the Contraceptive Pills Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Contraceptive Pills Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Afaxys Pharma, LLC, Amneal Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma Limited, Bayer AG, Bionpharma Inc., Cipla Limited, Combe Incorporated, Gedeon Richter PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Julie Product Inc., Lupin Limited, Mankind Pharma Ltd., Mayne Pharma Group Limited, Merck & Co., Inc., Northstar Rx LLC, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Limited, Syzygy Healthcare Solutions, LLC, Teva Pharmaceuticals, Viatris Inc., and Xiromed, LLC.

Market Segmentation & Coverage

This research report categorizes the Contraceptive Pills Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Combination Pill, Continuous/Extended Pill, and Progesterone Pill.
Based on Age Group, market is studied across 15-24, 25-34, 35-44, and 45 and Above.
Based on Drug Class, market is studied across Branded Drugs and Generic Drugs.
Based on Mode of Prescription, market is studied across Over-the-Mounter (OTC) and Prescription-Based.
Based on Distribution, market is studied across Offline and Online. The Offline is further studied across Clinics and Hospitals, Pharmacies, and Public Health Organizations.
Based on Route of Administration, market is studied across Oral and Viginal.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-A579C4315A23

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing use of contraceptive pills to prevent unintended pregnancies and rising awareness about family planning
  - 5.1.1.2. Growing prevalence of sexually transmitted diseases (STDs)
  - 5.1.1.3. Supportive government initiatives to encourage use of contraceptive pills
- 5.1.2. Restraints
  - 5.1.2.1. Incidences of product recalls & adverse health impacts of contraceptive pills
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in contraceptive pill formulations and packaging
  - 5.1.3.2. Availability of contraceptive pills through online channels
- 5.1.4. Challenges
  - 5.1.4.1. Safety and social concerns regarding pill usage and issues with product marketing
5.2. Market Segmentation Analysis
- 5.2.1. Product: Emerging adoption of combination pills owing to their broad applicability and additional health benefits
- 5.2.2. Route of Administration: Widespread acceptance, ease of access, and cost-effectiveness of oral contraceptives
- 5.2.3. Age Group: High usage of contraceptive pills in the age group 15 to 24
- 5.2.4. Distribution: Evolving online distribution channels for contraceptive pills
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Contraceptive Pills Market, by Product

6.1. Introduction
6.2. Combination Pill
6.3. Continuous/Extended Pill
6.4. Progesterone Pill

7. Contraceptive Pills Market, by Age Group

7.1. Introduction
7.2. 15-24
7.3. 25-34
7.4. 35-44
7.5. 45 and Above

8. Contraceptive Pills Market, by Drug Class

8.1. Introduction
8.2. Branded Drugs
8.3. Generic Drugs

9. Contraceptive Pills Market, by Mode of Prescription

9.1. Introduction
9.2. Over-the-Mounter (OTC)
9.3. Prescription-Based

10. Contraceptive Pills Market, by Distribution

10.1. Introduction
10.2. Offline
- 10.2.1. Clinics and Hospitals
- 10.2.2. Pharmacies
- 10.2.3. Public Health Organizations
10.3. Online

11. Contraceptive Pills Market, by Route of Administration

11.1. Introduction
11.2. Oral
11.3. Viginal

12. Americas Contraceptive Pills Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Contraceptive Pills Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Contraceptive Pills Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Perrigo launched the First OTC daily birth control pill in the U.S., aiming to expand reproductive health access and affordability.
- 15.3.2. UK launched trial for hormone-free male birth control YCT-529 aiming for regulatory approval and market entry by 2024
- 15.3.3. Richter and Mithra sign supply agreement for production of API for combined oral contraceptive Estelle and Donesta
- 15.3.4. FDA approves first nonprescription daily oral contraceptive
- 15.3.5. Gedeon Richter announces availability of oral contraception Drovelis
15.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Afaxys Pharma, LLC
3. Amneal Pharmaceuticals, Inc.
4. Apotex Inc.
5. Aurobindo Pharma Limited
6. Bayer AG
7. Bionpharma Inc.
8. Cipla Limited
9. Combe Incorporated
10. Gedeon Richter PLC
11. Glenmark Pharmaceuticals Limited
12. Johnson & Johnson Services, Inc.
13. Julie Product Inc.
14. Lupin Limited
15. Mankind Pharma Ltd.
16. Mayne Pharma Group Limited
17. Merck & Co., Inc.
18. Northstar Rx LLC
19. Perrigo Company plc
20. Pfizer Inc.
21. Piramal Enterprises Ltd.
22. Sun Pharmaceutical Industries Limited
23. Syzygy Healthcare Solutions, LLC
24. Teva Pharmaceuticals
25. Viatris Inc.
26. Xiromed, LLC